Views & Analysis Q&A: Albireo’s Ron Cooper on bile acid modulation While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.
News Novartis abandons Fabhalta trial in lupus nephritis A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.